Amovicomb® Antibiotic - penicillin semisynthetic + beta-lactamase inhibitor Powder for solution for intravenous administration. Zhelezol® The iron of the stomach secretion is a reducing agent - a proton pump inhibitor Lyophilizate for solution for infusion. Isodep® Antibiotic-cephalosporin Powder for the preparation of solution for intravenous and intramuscular injection 0.25 g, 0.5 g, 1.0 g or 2.0 g. Kispar® Antibiotic-macrolide Tablets, film-coated, 250 mg. Movigip® Antibiotic-cephalosporin Powder for the preparation of solution for intravenous and intramuscular injection 0.5 g, 1.0 g or 2.0 g. Movizar Antibiotic-cephalosporin Powder for the preparation of solution for intravenous and intramuscular injection 0.5 g, 1.0 g or 2.0 g. Movogleken® Hypoglycemic agent for oral use of the second-generation sulfonylurea group Tablets, 5 mg. Movoperiz® Antibiotic-cephalosporin Powder for the preparation of solution for intravenous and intramuscular administration of 1000 mg. Sulmover® Antibiotic-cephalosporin + β-lactamase inhibitor. Powder for the preparation of solution for intravenous and intramuscular injection of 1.0 g + 1.0 g of active substances. Sulmover® Antibiotic-cephalosporin + Dose changes may be required in case of severe bile duct obstruction, severe liver disease, as well as renal dysfunction associated with any of these conditions. In the treatment of cefoperazonom, as well as other antibiotics, in rare cases, vitamin K deficiency develops. Its cause is probably suppression of normal intestinal microflora, which synthesizes this vitamin.The risk group can include patients receiving malnutrition, patients with malabsorption (for example, in case of mu-koviscidosis) and for a long time on intravenous artificial feeding. In such cases, as well as in patients receiving indirect anticoagulants, it is necessary to monitor the international normalized ratio and, in the presence of indications, prescribe vitamin K. Long-term treatment with Sulmover®, like other antibiotics, can lead to an excessive growth of insensitive microorganisms. Patients should be carefully observed during treatment. With prolonged therapy, it is recommended to periodically monitor the performance of internal organs, including the kidneys, liver and hematopoiesis system. This is especially important for newborns, especially premature babies, and children under 1 year. Cefoperazone does not displace bilirubin from its association with plasma proteins. The efficacy and safety of the drug in infants and children under 1 year of age has not been adequately studied. Prior to the appointment of the drug, the potential benefit and the possible risk should be correlated. Lactamase inhibitor. Powder for the preparation of solution for intravenous and intramuscular injection.